A randomised placebo-controlled trial of Oxpentifylline (Trental) in erythropoietin-resistant anaemia (ERA) in chronic kidney disease

A randomised placebo-controlled trial of Oxpentifylline (Trental) in erythropoietin-resistant anaemia (ERA) in chronic kidney disease (2007–2012)

Abstract:

That Oxpentifylline (Trental) administration will effectively treat erythropoietin or darbepoietin-resistant anaemia in chronic kidney disease patients.

Grant type:

The Roche Foundation for Anemia Research

Researchers:

Professor David Johnson

NHMRC Leadership Fellow

Centre for Health Services Research

Faculty of Medicine
Professor Carmel Hawley

ATH - Professor

Princess Alexandra Hospital Southside Clinical Unit

Faculty of Medicine

Funded by:

The Roche Foundation For Anemia Research